Endocrine Abstracts

In males, peak bone mass as evaluated by DXA is reached at the age of 20–22 years and may be important for the risk of fracture later in life. DXA, however, only provides two-dimensional images and does not allow assessment of bone structure.We used HR-pQCT to assess trabecular and cortical volumetric BMD (vBMD) and bone microarchitecture at the distal radius and tibia in a population based study including healthy male volunteers. Moreover, bone str...

Objective: The cardiovascular effects of testosterone treatment are debated. Osteoprotegerin (OPG) is an independent marker of cardiovascular risk. We investigated the effect of testosterone therapy on OPG levels in ageing men with low normal bioavailable testosterone levels.Design: A randomized, double-blinded, placebo-controlled study of six months testosterone therapy (gel) in 38 men aged 60–78 years with bioavailable testosterone <7.3 nmol/l...

Background: The indication for testosterone therapy in ageing hypogonadal men without hypothalamic, pituitary or testicular disease remains to be elucidated. The aim of this study was to investigate the effect of testosterone therapy on insulin sensitivity, substrate metabolism, body composition and lipids in ageing men with relative hypogonadism using a predefined cut-off level for bioavailable testosterone.Methods: A randomized, double-blinded, placebo...